^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

    Excerpt:
    ......
    Trial ID:
    NCT00941499
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

    Excerpt:
    ...- Paraffin block from the primary tumor in order to perform tha mutational analysis of the KRAS gene...
    Trial ID:
    NCT00755534
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy.

    Published date:
    05/28/2020
    Excerpt:
    In this study, we monitored the ctDNA mutational changes in advanced CRC patients underwent first-line therapy with bevacizumab and cetuximab combined with chemotherapy. Patients with KRAS and TP53 mutations in tissues appeared to benefit more than the wild-type counterpart. 
    DOI:
    10.1200/JCO.2020.38.15_suppl.e15524